17 results about "Antibiogram" patented technology

The invention discloses MoSe2 nano-enzyme-selenium-rich probiotic composite hydrogel and a preparation method and application thereof, the composite hydrogel comprises a hydrogel matrix and functional components dispersed in the hydrogel matrix, and the functional components comprise anti-MoSe2 nano-enzyme and selenium-rich probiotics wrapped by an antioxidant film. According to the MoSe2 nano-enzyme-selenium-enriched probiotic composite hydrogel provided by the invention, the sonodynamic characteristics of the MoSe2 nano-enzyme and the biological activity of the selenium-enriched probiotics are perfectly fused: under ultrasonic stimulation, the MoSe2 nano-enzyme not only can directly and efficiently generate reactive oxygen species (ROS), but also can catalyze low-concentration hydrogen peroxide to generate a large amount of hydroxyl radicals (. OH); broad-spectrum killing of various pathogenic bacteria is achieved, and the risk of drug resistance evolution of bacteria is reduced from the source; meanwhile, antibiotics secreted by the selenium-enriched probiotics can form a synergistic sterilization effect, so that the pathogenic bacterium removal effect is further enhanced.

This invention discloses a biocontrol agent for controlling sesame wilt, belonging to the field of pesticide technology. The raw materials of this biocontrol agent for controlling sesame wilt, by weight, include: 8-15 parts of a pyrimidine nucleoside antibiotic, 0.5-5 parts of matrine, 0.5-2 parts of an antioxidant, 1-5 parts of a dispersant, 1-3 parts of an adhesive, and 2000 parts of water. This invention utilizes a mixture of the pyrimidine nucleoside antibiotic and matrine to achieve a synergistic effect. The mixed product system allows matrine to enter the plant more easily, further improving its rapid action and systemic absorption. Furthermore, by simultaneously utilizing the different bactericidal mechanisms of the pyrimidine nucleoside antibiotic and matrine, the problem of the slow onset of action of the pyrimidine nucleoside antibiotic is addressed, thus enabling faster and more effective control of sesame wilt.

The invention provides an application of an HDAH inhibitor in preparation of antibiotics. According to the invention, research finds that escherichia coli has Zn < 2 + >-dependent histone deacetylase-like amide hydrolase-HDAH, and the HDAH can directly influence the enzyme activity of metabolic enzyme through acetylation modification so as to regulate and control the metabolic level of bacteria; and the transcription level of metabolism-related genes can be indirectly regulated by acting on a transcription regulation factor (such as histone-like protein HU), and the metabolism of escherichia coli is synergistically regulated from two levels of post-translational modification and transcription. The invention also finds that the vorinostat (SAHA), the trichosaliocin (TSA) and the like can be combined with the HDAH and inhibit the deacetylation activity of the HDAH, are HDAH inhibitors, and inhibit the growth and migration ability of escherichia coli after being administered to the escherichia coli.

A process and system for removal of antibiotic compounds from a patient's body can include having a patient digest an antibiotic removal agent or an antibiotic deactivation agent. The agent can include anionic hairy cellulose nanocrystals (AHCNC) hybridized with a resin, such as cholestyramine (CHA). The agent can pass through the patient's digestive system to remove antibiotic compounds that may reside therein as a consequence of an antibacterial treatment provided to the patient. Removal of the antibiotic compounds from the patient's digestive system can avoid evolution of antimicrobial resistance.

A system for detecting infection is provided. The system includes a pathogen detection component for detecting a pathogen, a host immune response component for detecting a host immune response associated with the pathogen, and an antimicrobial resistance component for detecting an antimicrobial resistance associated with the pathogen.

The invention provides a helicobacter pylori culture medium, a culture method and application thereof, and relates to the technical field of microbiological culture.The helicobacter pylori culture medium comprises a basic culture medium and antibiotics, and when the basic culture medium is a brain heart infusion agar culture medium, the basic culture medium is a solid culture medium and is used for activation by adding defiberized sheep blood or goat serum; when the basic culture medium is a Brinell broth culture medium, the basic culture medium is a liquid culture medium, essential amino acid is provided by adding L-cysteine, and the basic culture medium is used as a reducing agent, so that enrichment culture of anaerobic bacteria is facilitated. Meanwhile, ferric pyrophosphate, L-cysteine and antibiotics are combined for use, so that rapid growth of the helicobacter pylori is promoted, pollution caused by infectious microbes is effectively reduced, and a more stable growth environment is provided for the helicobacter pylori; data show that when the culture medium is used for culturing helicobacter pylori, compared with a traditional solid culture method, the yield of collected wet thalli is increased by nearly three times, and the high survival rate can be kept while high-speed multiplication culture of helicobacter pylori can be achieved.

The invention discloses a preparation method of a nasal cavity hemostasis composite sponge and a product thereof, and the preparation method comprises the following steps: (1) adding quantitative konjac glucomannan (KGM) into an aqueous solution, and swelling overnight; adding sodium alginate (SA) and sodium polyacrylate (ASAP) in batches according to the proportion, heating, and uniformly stirring; (2) adding an antibiotic aqueous solution into the solution, and continuously heating and stirring; (3) taking out the solution, pouring into a mold, pre-freezing, and freeze-drying; and (4) immersing the sample into a calcium chloride aqueous solution for cross-linking treatment, cleaning, pre-freezing, and freezing to obtain the required composite sponge material. The nasal cavity hemostasis composite sponge prepared by the invention has the effects of compression hemostasis, blood coagulation, microenvironment repair and inhibition of microorganisms such as bacteria and fungi.

Methods and systems for detection and identification of pathogens and antibiotic resistant genes are disclosed herein. The method is a high throughput, rapid comprehensive method for identification of pathogens in a sample or subject. The method, according to embodiments herein, is also capable of identifying genes responsible for Antimicrobial Resistance (AMR) in a pathogen. The said method provides a rapid, cost-effective and scalable solution for identifying pathogens.

The present invention provides a method for determining the resistance of a microorganism to a drug by detecting at least a transcript of a drug resistance gene from a microorganism in a biological sample, the method comprising the steps of: (i) lysing the cells by means of a chemical or a mechanical method, thereby obtaining a lysate and cell debris; (ii) obtaining a ribosome-antibody complex from the lysate using an antibody or a fragment thereof which binds specifically to a microorganism-ribosomal protein; (iii) purifying the mRNA associated to the ribosome-antibody complex by means of a nucleic acid extraction method; and (iv) submitting the resulting mRNA to a specific gene detection method, thereby identifying the at least one drug resistance gene transcript of the biological sample. Provided methods and kits allow determining the resistance to antibiotics of a biological sample in a rapid and reliable manner, thereby minimizing the risk of AMR and allowing the definition of the therapeutic potential of a selected antibiotic

The invention discloses a self-assembled nano synergistic antibacterial system constructed on the basis of Surfactin and application of the self-assembled nano synergistic antibacterial system in prevention and control of filamentous fungi. According to the preparation method, the excellent amphipathy of Surfactin is utilized, the emulsifying effect and the bactericidal synergistic effect of Surfactin are exerted at the same time, hydrophobic antibacterial active ingredients are self-assembled and wrapped to form stable nano-particles with the particle size being 20-200 nm and the PDI being smaller than or equal to 0.3 in the mass ratio of 1: 5 to 2: 1, and the FIC is smaller than or equal to 0.5 and the strong synergism is achieved. The system has the characteristic of dual purposes by one dose: Surfactin not only assists the hydrophobic antibacterial active component to penetrate through the fungal cell wall, but also cooperates with the hydrophobic antibacterial active component to trigger significant outbreak (5.8 times at most) of the active oxygen level in fungal cells, and cooperatively induces programmed death of the fungal cells. The hydrophobic active ingredients comprise plant essential oil (such as cinnamyl aldehyde), microbial source antibiotics (such as echinocandin) and broad-spectrum hydrophobic chemical bactericides (such as triazole and methoxy acrylate). The nano synergistic antibacterial system is simple in preparation process, full in biological source and free of chemical residues, the unexpected technical effects that the dosage of active ingredients is reduced by 70% or above, and the field control effect reaches up to 85% are achieved, the limitation of the known technology is remarkably overcome, and the nano synergistic antibacterial system has wide application prospects in the fields of green agriculture and food safety.

This invention relates to the field of biopharmaceutical technology, specifically to a BTO / PB acoustic pressure electrocatalytic nanoplatform ointment, its preparation method, and its application. The ointment is an injectable BTO / PB acoustic pressure electrocatalytic nanoplatform ointment formed by combining a barium titanate and Prussian blue composite nanomaterial with an ointment. The BTO / PB acoustic pressure electrocatalytic nanoplatform ointment of this invention exhibits excellent biocompatibility. Unlike traditional antibiotics, BTO / PB generates ROS (reactive oxygen species) through an ultrasound-driven catalytic reaction, independent of antibiotics, thus eliminating the risk of drug resistance. It effectively addresses the increasingly serious problem of antibiotic resistance, has a good antibacterial effect against periodontal pathogens, significantly alleviates gingival inflammation, reduces the infiltration of inflammatory cells, lowers the expression of inflammatory factors, and effectively inhibits osteoclast activity, thereby protecting alveolar bone and maintaining the integrity of periodontal tissues.

Blood and lung infections are a worldwide health problem with approximately five million deaths each year. Early treatment could help save lives, but better tests to identify these infections are needed. This invention identifies pathogens, particularly those that are resistant to antibiotics, faster. This invention allows for appropriate antibiotic treatment at an earlier time point. Data from deep RNA sequencing of human blood is used to create a faster diagnostic test for infections and associated antimicrobial resistance.

This invention discloses a laser assisted cold plasma device for overcoming the antimicrobial resistance and effectively killing the microbes. The microbes are first illuminated with laser light, which inactivates the antioxidant enzyme of the microbes and renders them susceptible to reactive oxygen species (ROS) attack. The microbes are then treated and killed with cold plasma. The synergy between the two treatments improves the effectiveness of microbe eradication by several orders of magnitude.

This invention relates to a staple peptide with enhanced broad-spectrum antibacterial activity, its preparation method, and its applications. Using an amino resin as a carrier, the peptide chain is synthesized in a DIC-Oxime condensation system according to the template Chem-KVL:Ac-KVLGRLVKVLGRLV-NH2 amino acid sequence via Fmoc solid-phase synthesis. During synthesis, while retaining key amino acid residues, S5 is substituted at specific positions to replace the original amino acid. The linear peptide is then cyclized in a dichloroethane solution with Grubbs I reagent to obtain the target staple peptide. The method of this invention is simple, easy to implement, and yields high purity and high efficiency. Further experiments have confirmed that the staple peptide of this invention exhibits significant broad-spectrum antibacterial activity, including activity against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. In the pharmaceutical field, it can serve as an excellent alternative to antibiotics and has potential application value in in vitro and in vivo antibacterial therapy.

This provides an accurate method for detecting carbapenemase production. [Solution] A method for determining the presence of zero, one or more Ambler class carbapenemases expressed by intestinal bacteria, comprising the steps of: providing a sample containing the intestinal bacteria; applying the intestinal bacteria in the test sample to a plurality of at least four test compositions over a duration, each of which comprises a growth medium and an antibiotic, and at least one of the test compositions further comprising at least one carbapenemase inhibitor; and determining the presence of zero, one or more Ambler class carbapenemases expressed by the intestinal bacteria by detecting the presence or inhibition of growth of the intestinal bacteria in each of the test compositions after the duration.

The present invention relates to a method for preparing a bactericidal phage vector, (pharmaceutical) compositions comprising such phage vectors, also for use in treating diseases, particularly those caused by (antimicrobial resistance) bacterial cells.

Disclosed is a compound ARM-1 and methods of treating a subject with a bacterial infection or preventing a bacterial infection therewith. ARM-1 functions to prevent the evolution of antimicrobial resistance in bacteria by targeting an evolability factor, Mfd, to prevent the development of antibiotic resistance. By inhibiting the evolution of antibiotic resistance, ARM-1 can be clinically administered to an array of subjects to prevent acceleration and advancement of bacterial infections.